Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Dalfampridine
Drug ID BADD_D00574
Description Dalfampridine is a potassium channel blocker used to help multiple sclerosis patients walk. This is the first drug that was specifically approved to help with mobility in these patients. FDA approved on January 22, 2010.
Indications and Usage Dalfampridine is a neurofunctional modifier that helps improve walking speed in patients with multiple sclerosis (MS).
Marketing Status approved
ATC Code N07XX07
DrugBank ID DB06637
KEGG ID D04127
MeSH ID D015761
PubChem ID 1727
TTD Drug ID D08YIN
NDC Product Code 10144-427; 63190-0510; 67877-444; 56125-427; 0591-2533; 65862-917; 62756-429; 63629-9450; 65862-863; 38779-3205; 42571-338; 51927-5030; 42571-275; 0378-4504; 12817-054; 46016-5042; 54382-125; 62756-038; 62991-3143; 65372-1157; 16729-292; 63190-0530; 51407-246; 0054-0479
UNII BH3B64OKL9
Synonyms 4-Aminopyridine | 4 Aminopyridine | Dalfampridine | Pymadine | VMI-103 | VMI 103 | VMI103 | 4-Aminopyridine Sustained Release | 4 Aminopyridine Sustained Release | Sustained Release, 4-Aminopyridine | Fampridine-SR | Fampridine SR
Chemical Information
Molecular Formula C5H6N2
CAS Registry Number 504-24-5
SMILES C1=CN=CC=C1N
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Cerebral disorder17.02.10.0170.001184%Not Available
Vulvovaginal pruritus23.03.12.009; 21.08.02.0040.001830%Not Available
Colitis microscopic07.08.01.0110.001184%Not Available
Temperature intolerance08.01.09.0220.002746%Not Available
Urine odour abnormal20.02.01.0200.009313%Not Available
Paraesthesia oral07.05.05.035; 17.02.06.0080.001830%Not Available
Cognitive disorder19.21.02.001; 17.03.03.0030.008129%
Dysgraphia17.02.03.0060.017927%Not Available
Restless legs syndrome17.02.07.008; 15.05.03.0120.002100%Not Available
Angiopathy24.03.02.007--Not Available
Adverse event08.06.01.0100.023956%Not Available
Bladder disorder20.03.01.0020.005491%Not Available
Connective tissue disorder10.04.04.026; 15.06.01.006--Not Available
Infestation23.11.01.002; 11.09.01.001--Not Available
Limb discomfort15.03.04.0140.006676%Not Available
Mediastinal disorder22.09.03.001--Not Available
Mental disorder19.07.01.002--Not Available
Motor dysfunction15.05.06.006; 17.01.02.0310.004576%Not Available
Spinal cord disorder17.10.01.0100.000538%Not Available
White blood cell disorder01.02.05.0020.001830%Not Available
Ill-defined disorder08.01.03.0490.008775%Not Available
Urinary tract obstruction20.08.01.0040.000538%
Adverse drug reaction08.06.01.0090.060833%Not Available
Autoimmune disorder10.04.04.0030.000538%
Renal impairment20.01.03.0100.013889%Not Available
Poor quality sleep17.15.04.002; 19.02.05.0050.002100%Not Available
Urethritis noninfective20.07.02.0020.000538%Not Available
Facial spasm17.04.03.0100.001184%Not Available
Head titubation17.01.06.0060.001184%Not Available
Adverse reaction08.06.01.0180.003015%Not Available
The 8th Page    First    Pre   8 9    Next   Last    Total 9 Pages